# Treatment of Aggressive Localized Lymphoma

> **NCT00841945** · PHASE3 · TERMINATED · sponsor: **French Innovative Leukemia Organisation** · enrollment: 334 (actual)

## Conditions studied

- B Cell Lymphoma

## Interventions

- **DRUG:** rituximab
- **DRUG:** doxorubicin
- **DRUG:** vincristine
- **DRUG:** prednisone
- **PROCEDURE:** radiotherapy

## Key facts

- **NCT ID:** NCT00841945
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** 2016-01
- **Final completion:** 2017-02
- **Target enrollment:** 334 (ACTUAL)
- **Why stopped:** other drugs other studies
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00841945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00841945, "Treatment of Aggressive Localized Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00841945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*